To: JOEY who wrote (4362 ) 3/2/1998 2:50:00 AM From: JIN CHUN Respond to of 27968
Jake, I wholeheartedly agree with you. As you can see from my previous response to LE, when you look at other companies in the same industry, the valuations should, IMO, put FAMH at least over $1.00/share, and when you look at STFF, which I had detailed previously, the same valuation would put FAMH much higher, especially when you consider the growth that the company has achieved since any thread on FAMH has been active. In the STFF example, earnings of just .01 eps would make FAMH fairly valued at current prices. Multiply that by their future earnings potential and would anyone really be able to say that they are overvalued? There has been a lot of talk about future dilution, the credit line, etc. My money, obviously, is on the assumption that the percentage of dilution, if any, will be far outweighed by the increase in revenue and eps. Why? Look at the Myriad deal. It diluted the number of shares by less than 5 percent while bringing in at least .05 eps for '98. Once again, you would need more than your feet and your hands to count the number of companies that are trading over $1, $2, even $3 a share which either have negative earnings or do not yet have a product, or worse, are banking on a speculative future product that has R&D costs that will probably never exceed market potential. LE mentioned CVIA before. Although I am sympathetic to that company and the efforts of the CEO, let's face it: it had no revenue and was only a public shell. Firamada has grown through acquisition and if any would like to place a gentlemen's bet that they will have positive earnings in '98 than I will take them up on it. Jin.